3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
Carboplatin
5
Cisplatin
3
zipalertinib
2
Pemetrexed
2
Paclitaxel
2
Nivolumab
2
Blood Specimen Collection
2
zimberelimab
1
selpercatinib
1
sacituzumab govitecan
1
repotrectinib
1
pembrolizumab
1
durvalumab
1
atezolizumab
1
alectinib
1
Toll-Like Receptor 1
1
Surveys and Questionnaires
1
One-Lung Ventilation
1
Ipilimumab
1
Health Records, Personal
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
durvalumab
×
90 days
×
Clear all
NCT06606847
2026-05-15
LADOGA
AstraZeneca
Phase 2
Active not recruiting
30 enrolled